# The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

> **NCT05238363** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 20 (estimated)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma

## Interventions

- **DRUG:** HLX07

## Key facts

- **NCT ID:** NCT05238363
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-15
- **Primary completion:** 2023-05-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05238363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05238363, "The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05238363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*